One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT04851457

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04851457
Other papers using this trial's data
  • Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy: The OPTIMISTIC Randomized Clinical Trial JAMA network open, 2025-04-01 DOI, PubMed 40244586, PMC12006867 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04851457. Randomized; single masking; primary purpose treatment. Start 2021-04-06 (actual); primary completion 2023-07-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China
Acronym
OPTIMISTIC
Intervention (Drug)
Intravenous tirofiban combination therapy
Lead sponsor
Shanghai East Hospital (class: other)
Collaborator
Shanghai 6th People's Hospital (class: other)
Collaborator
Ningbo No. 1 Hospital (class: other)
Collaborator
Zhangzhou Municipal Hospital of Fujian Province (class: other)
Collaborator
Shanghai 7th People's Hospital (class: other)
Collaborator
Jinan Central Hospital (class: other)
Collaborator
Xuchang Central Hospital (class: other)

Record details

Record id
cardio:ct-nct04851457
Content hash
3180d46ca63706c194c45e5bf1a846a204931e6a7b78cd7874b71cfbd048ec34